<DOC>
	<DOCNO>NCT00452257</DOCNO>
	<brief_summary>The primary objective study see enzastaurin affect pGSK3 beta level B-cell chronic lymphocytic leukemia ( B-CLL ) cell .</brief_summary>
	<brief_title>A Study Enzastaurin Patients With Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Patients eligible include study meet follow criterion : 1 . Patients Bcell CLL diagnose expression CD19 , CD5 , CD23 flow cytometry . 2 . Rai Stage III IV disease earlier stage disease indication therapy per NCI Working Group criterion ( Cheson et al . 1996 ) 3 . Absolute lymphocyte count &gt; = 5,000/microliter , lymphocyte WBC differential &gt; = 70 % . 4 . Platelet count &gt; 20,000/microliter . 5 . Adequate organ function , include follow : Hepatic : bilirubin &lt; = 1.5 time upper limit normal ( x ULN ) ; alkaline phosphatase ( ALP ) , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) &lt; = 2.5 x ULN Renal : serum creatinine &lt; = 1.5 X ULN . Patients exclude study meet follow criterion : 1 . Are unable swallow tablet . 2 . Are unable discontinue use carbamazepine , phenobarbital , phenytoin . 3 . Are pregnant breastfeeding . 4 . Have central nervous system ( CNS ) metastases ( unless patient complete successful local therapy CNS metastases corticosteroid least 4 week start study therapy ) . 5 . Have serious concomitant systemic disorder ( include active bacterial , fungal , viral infection ) , opinion investigator , would compromise patient 's ability adhere protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>